The synthesis and characterization of new pyran derivatives (1–3) were realized by means of infrared spectroscopy (IR), 1H nuclearmagnetic resonance spectroscopy (1H NMR), high resolution mass spectrum (HRMS) and single crystal X-ray crystallography. The anti-proliferation activity of compounds 1–3 was investigated against human ovarian cancer cells CAOV3 by Cell Counting Kit-8 (CCK-8) assay. The RT-PCR assay was performed to detect the relative expression level of the Foxm1b in the CAOV3 cell line after treated with compounds 1–3. Furthermore, molecular docking studies supported the biological assay data and suggested that compared with compounds 1 and 3, compound 2 has stronger interaction with protein.
AthanE., CabiltesI., CoghillS., BoweS.J.Silent but deadly: patients with enterococcal bacteraemia should be assessed for colorectal neoplasia, Med J Aust210 (2019)86.
2.
SongW., YinW., ZhangZ., HeP., YangX., ZhangX.A DNA functionalized porphyrinic metal-organic framework as a peroxidase mimicking catalyst for amperometric determination of the activity of T4 polynucleotide kinase, Mikrochim Acta186 (2019)149.
3.
NaY.S., ParkS.G.A Rare Case of Spontaneous Tumor Lysis Syndrome in Idiopathic Primary Myelofibrosis, Am J Case Rep20 (2019)146–150.
4.
Gundín-MeníndezS., SantosV.M., Parra-RobertM., PlaX.F., FraderaJ.M.A. and PortoR.M., Serum CA 19.9 Levels in Patients With Benign and Malignant Disease: Correlation With the Serum Protein Electrophoretic Pattern, Anticancer Res39 (2019)1079–1083.
5.
LuH., WangX., ZhangW., LiuY.Two Novel Pyran-Ketone Derivatives: Synthesis, Crystal Structures and Inhibiting Thyroid Adenoma Cell Activity, In Vitro, Lat Am J Pharm36 (2017)1289–1293.
6.
EshghiH., ZohuriG.H., SandaroosR., DamavandiS.Synthesis of novel benzo[f]chromene compounds catalyzed by ionic liquid, Heterocycl Commun18 (2012)67–70.
7.
SheldrickG.M.SHELXL-97, Program for Solution Crystal Structure and Refinement. University of Göttingen: Göttingen, Germany, 1997.
8.
KupcsikL.Estimation of cell number based on metabolic activity: the MTT reduction assay, Methods Mol Biol740 (2011)13–19.
9.
FanX.X., ShenP., ZhouX.H.Novel Pyran and Polyhydroquinoline Derivatives:Inhibiting Human Osteosarcoma Activity, Russ J Gene Chem88 (2018)1247–1251.
